产品
编 号：F071983
产品类型
规格
价格
是否有货
结构图
CAS No: 120993-53-5
产品详情
生物活性：
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction.
体内研究：
Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation.Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.).Animal Model:Male mongrel dogs model of cardiopulmonary bypass
Dosage:1.0 mg/kg + 0.75 mg/kg/h, 1.0 mg/kg + 1.50 mg/kg/h, 1.0 mg/kg + 2.25 mg/kg/h, 1.0 mg/kg + 3.0 mg/kg/h.
Administration:Administered as a bolus plus infusion
Result:Inhibited clot formation with no adverse hemodynamic or hematologic effects.
Animal Model:Rat shunt model of thrombus formation on a cotton-thread
Dosage:0.01-1 mg/kg approximately
Administration:Intravenous injections, subcutaneous injection
Result:Inhibited thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.).Inhibited venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.).
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction.
体内研究：
Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation.Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.).Animal Model:Male mongrel dogs model of cardiopulmonary bypass
Dosage:1.0 mg/kg + 0.75 mg/kg/h, 1.0 mg/kg + 1.50 mg/kg/h, 1.0 mg/kg + 2.25 mg/kg/h, 1.0 mg/kg + 3.0 mg/kg/h.
Administration:Administered as a bolus plus infusion
Result:Inhibited clot formation with no adverse hemodynamic or hematologic effects.
Animal Model:Rat shunt model of thrombus formation on a cotton-thread
Dosage:0.01-1 mg/kg approximately
Administration:Intravenous injections, subcutaneous injection
Result:Inhibited thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.).Inhibited venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备